PWS is a multisystem disorder, requiring multidisciplinary management and treatment. One mainstay of the management is growth hormone (GH) supplementation because of its proven benefits on reduction of adipose tissue, increase in lean body mass, and taller final height.
11-14 GH replacement may have other indirect, beneficial effects as well. Haqq and colleagues noted changes in overall pulmonary function (e.g., increase in peak flow, increased vital capacity, trends towards decreased numbers of apneic/hypopneic events) with weekly injections. 15 More ominously, however, several case reports have questioned whether a link exists between GH therapy and subsequent fatal sleep apnea. [16] [17] [18] The role, if any, of GH in improving sleep disturbances is unclear, especially since sleep apnea due to obesity is not the only sleep abnormality. We report the PSG findings of a retrospective cohort of PWS patients, some of whom have been treated with daily GH supplementation. In addition, we assessed the tive correlation between the BMI z and AHI. The BMI z was significantly different between GH-treated and -untreated groups, but there was not a significant difference between AHI, CA, oxygen nadir, or maximum carbon dioxide tension of the GH-treated and -untreated groups. There was no significant correlation between the MSLT and the sleepiness scale or AHI. There was also no significant difference between the AHIs of patients with different genetic defects. conclusions: There should be a low threshold for obtaining PSG to evaluate SDB, but the type and severity of SDB were not predictable based on a sleepiness scale score, BMI z , or underlying genetic defect. Keywords: Prader-Willi syndrome; breathing, sleep-disordered; polysomnography; obstructive sleep apnea; snoring; growth hormone citation: Williams K; Scheimann A; Sutton V; Hayslett E; Glaze DG. Sleepiness and sleep disordered breathing in Prader-Willi syndrome: relationship to genotype, growth hormone therapy, and body composition.
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prevalence of SDB in this cohort, the relationship between SDB and readily available clinical measures, and the difference in the prevalence of SDB between GH-treated and GH-untreated groups.
MetHoDS

Selection criteria
This retrospective study was approved by the Baylor College of Medicine Affiliated Institutional Review Board and performed at 15m above sea level. The patient cohort was identified from patients followed by one of the authors (AS) at Texas Children's Hospital PWS Clinic and from review of PSG records by the medical director (DG) of TCH Children's Sleep Center. Only patients who had their initial PSG during the study period of January 2000 through January 2005 were included in the cohort. Patients were referred for PSG if there was any concern for SDB. Patients were prescribed GH replacement based on the following criteria: confirmation of genetic diagnosis of Prader-Willi syndrome and either evidence of growth failure or documentation of GH deficiency by provocative testing (prior to FDA approval of GH treatment in June 2000).
genetic testing
The molecular basis of PWS was established for all patients in the study. A variety of commercial labs that are both CAPand CLIA-certified performed methylation studies, fluorescence in situ hybridization (FISH) studies, testing for uniparental disomy and sequencing of the 15q11.2 imprinting center. For those found to have a deletion by FISH, no further molecular testing was performed. When the first test performed was DNA methylation study of the PWS region, subsequent FISH analysis was performed. In families where recurrence risk was a concern, analysis for uniparental disomy was performed. In those with abnormal methylation studies, no deletion by FISH and biparental inheritance of 15q11.2, the PWS/AS imprinting center was sequenced.
PSg evaluation
A sleepiness score was determined from a modified Epworth Sleepiness Scale (see appendix) and was completed by a proxy (parent) for each patient. Score range is 0-24 (score >10 suggests a tendency for daytime sleepiness in adults). All patients underwent attended overnight PSG of at least 8 hours duration. The patients were put to bed at their usual bedtimes. No hypnotic was given.
MSLT studies consisted of 5 nap sessions, beginning 2 hours after getting out of bed in the morning; nap sessions were at least 20 minutes and were timed two hours apart. These studies were completed in the sleep laboratory of the TCH Children's Sleep Center.
The following parameters were recorded using a MedCare Rembrandt digital system and software: 6 channels electroencephalography (EEG); eye movements; chin electromyography; airflow (nasal pressure transducer; oral thermocouple); respiratory effort (chest and abdominal piezo-strain gauges); oxygen saturation (pulse oximeter with recording of pulse waveform to verify values); end-tidal carbon dioxide (ETCO 2 ) levels (nasal catheter), but not percentage of total sleep time or occurrence during which stage of sleep; electrocardiogram (one channel); extremity movement (accelerometers); observations by sleep technologist in constant attendance; and time-synchronized video recording for characterization of behaviors. Respiratory monitors were not used during MSLT. Scoring of the sleep studies, MSLT, and EEG were interpreted by a board-certified sleep medicine physician (DG); computerized scoring was not utilized. Sleep staging was scored using standard methodology. 19 Total sleep time and sleep efficiency were calculated based on the time from lights out to lights on during the overnight study. Sleep latency was calculated by the first epoch of any stage of sleep. Minimum oxygen saturation values and maximum ETCO 2 values were recorded. All obstructive apnea events (respiratory effort and no airflow for the duration of two or more breaths) and obstructive hypopnea events (two or more breaths' duration with 30% decrease in airflow by nasal pressure transducer and ≥ 3% drop of oxygen saturation values from baseline oxygen saturation values) were scored. Central apneic events (no respiratory effort and no airflow ≥ 20 sec, or shorter events with ≥ 3% drop in oxygen saturation values from baseline values) were scored. For obstructive respiratory events and central apneic events, an index (number per hour of sleep) was calculated. Periodic limb movements (PLMs) were scored according to the American Academy of Sleep Medicine guidelines, and significant values were considered to be ≥ 5 PLMs per hour of sleep. 20 An MSLT was not obtained if: AHI was > 30; AHI was ≥ 20 and oxygen saturation fell below 75% (in which case a splitnight study was performed); the patient required admission to the hospital for severe OSA; or if the patient was unable or unwilling to stay. The latency to any REM episode, the mean sleep latency to the first 30 second epoch and stage of sleep, the latency to any REM episode, and number of sleep-onset REM episodes were recorded.
PSG parameters were recorded into a spreadsheet for further analysis (Microsoft Excel 2003, Redmond, WA), including: sleep duration, REM and NREM sleep latency, sleep architecture, apnea/hypopnea or respiratory distress index, frequency of central apneas, arousal index, oxygen saturation nadir, peak ETCO 2 level, periodic limb movements, presence of snoring, MSLT findings, and visual analysis of the electroencephalogram.
Normalized Body Mass indices (BMi z )
Normalized body mass indices corrected for age, sex, and ethnicity (BMI z ) were obtained using the BMI z-score calculator from the body composition lab at the Children's Nutrition Research Center (Shypailo RJ, Carter J [2005] Children's BMI-percentile-for-age Calculator. Retrieved 1/27/2006 from the Baylor College of Medicine, Children's Nutrition Research Center website: www.kidsnutrition.org/bodycomp/bmiz2.html) and were obtained within 6 months of the PSG, so that patients of different ages could be compared; for children less than 2 years of age, the BMI z was determined using weight-height measurements.
Sleep-Disordered Breathing in Prader-Willi Syndrome
Statistical Analysis
All statistical analyses were performed using Microsoft Excel 2003 (Redmond, WA) and Prism 4 for Windows (Graphpad Software, San Diego, CA) with p < 0.05 considered significant.
ReSULtS
Thirty-seven patients met the inclusion criteria for this review; the population data are detailed in Table 1 . The average age was 9 years (standard deviation [SD] 6 yr; range 15 mo-24 yr). Fifty-four percent of the patients were male. Several genetic defects have been described for PWS; the frequency of these defects in this cohort were roughly similar to published prevalences: 59% with a deletion; 32% with maternal UPD; and 8% with imprinting. 2 The mean BMI z was 1.9 (SD 1.4), a value highly correlated with the percent body fat in this cohort (Spearman correlation coefficient r 2 = 0.36, p < 0.001). Selected PSG data are described in Table 2 (apnea-hypopnea index, central apnea index, oxygen saturation nadir, peak ET-CO 2 tension, multiple sleep latency). Other data are not shown but are available, including weight, lean body mass, and fat percentage, arousal index, and normality of EEG.
Of note (data not shown): mean total sleep time was 408 min (SD 142); sleep efficiency was 85% (SD 12); sleep latency was 17 minutes (SD 16); REM latency was 84 minutes (SD 57); percentage of total sleep time in stage 1, 2, slow wave, and REM sleep was 12%, 40%, 26%, and 21%, respectively; arousal index was 12/h (SD 9). These findings are in keeping with published normative data. 21 Six percent of the electroencephalograms (2/31) were considered abnormal. The patients' families completed a sleepiness scale to assess subjective daytime sleepiness: a score above 10 (16 of 30 completed questionnaires) is considered to signify a tendency for daytime sleepiness in adults. Fifty-four percent (20/37) of the patients underwent a MSLT during the daytime following their overnight study. Twenty-two percent (8/37) of the patients underwent split-night studies with continuous positive pressure titration.
Some form of SDB (as defined by: snoring, greater than one obstructive apnea or central apnea per hour, ETCO 2 greater than 50 mm Hg, and/or an oxygen desaturation <93%) was observed in all 37 patients (see Table 3 ). 21 The most common SDB abnormality (86% of patients) was oxygen desaturation to less than 93%; of those, the mean desaturation was 78%. The next most common abnormality (70%) was elevated AHI; of those, the mean AHI was 20/h and the median was 8. Twentythree patients (62%) exhibited hypercarbia; of those the mean ETCO 2 was 62 mm Hg. Five patients had only one abnormality, 8 exhibited two abnormalities, 17 exhibited three abnormalities, and 7 exhibited four abnormalities. Half of the patients (17/33) snored. Notably, three patients (patients 25, 31, and 33) who had undergone tonsillectomy/adenoidectomy before the study and one patient (patient 17) receiving noninvasive ventilation still exhibited hypoxemia (see Table 2 ). The mean sleep efficiency was 84% (SD 11%), the mean sleep latency was 17 minutes (SD 16 minutes), and the REM latency was 84 minutes (SD 57 min). Only one patient had significant PLMs (38/h of sleep); all others had <5 PLM/h of sleep.
Sixteen patients in the cohort were receiving daily GH injections at the time of their initial PSG (mean dose = 0.22 mg/kg/ week) and had been treated for an average of 4.8 years (range 1.5-12 years). There was no significant difference in age (106 ± 52 months treated, 111 ± 82 months untreated, p = 0.8) between groups. Sixty-two percent of the untreated group were male compared with 44% of the treated group (Fisher exact test, p = 0.33). The mean BMI z scores (1.4 and 2.5 for the treated and untreated groups, respectively) were significantly different (unpaired t-test, p = 0.005). However, there were no statistically significant differences of the AHI, central apnea, oxygen nadir, or maximum ETCO 2 between the treated and untreated groups (Table 4 ). In the entire cohort, there was a positive correlation between the AHI and BMI z (Pearson correlation coefficient r 2 = 0.16, p = 0.01). None of these patients receiving GH, followed between 1.5 and 12 years, has died (AS, personal communication).
Additionally, 20 patients underwent an MSLT, an objective measure of daytime sleepiness. Five of the 20 MSLTs were consistent with narcolepsy and were characterized by 2 or more sleep-onset REM episodes and an average MSLT latency of 5.9 minutes. Cataplexy was not reported or recorded in any patients. There was no correlation between the sleepiness scale score and average MSLT sleep latency (Spearman correlation coefficient r 2 = 0.03, p = 0.48); AHI and MSLT sleep latency (r 2 = 0.008, p = 0.72); or the BMI z and MSLT sleep latency (r 2 = 0.004, p = 0.80). Lastly, we considered whether the type of underlying genetic abnormality (e.g., deletion) was associated with sleep disordered breathing. We therefore compared the AHI with the underlying genetic abnormality (i.e., deletion, uniparental disomy, or imprinting), but found no significant difference between the groups (one-way ANOVA, F = 0.32, p = 0.72; Table 4 ).
DiScUSSioN
PWS is a syndrome with an estimated incidence of 1:10,000-25,000 births marked by neonatal hypotonia, mental retardation, and evidence of hypothalamic dysfunction (e.g., infertility, childhood obesity,). 1, 22 Although SDB is a minor criterion for the diagnosis, several series have found a high prevalence of SDB in these patients. 22, 24, 25 From a PWS population study from England, 20% of pediatric and adult patients reported sleep disturbances. 26 In small Others have posited a central cause for sleep disturbances. One study reported low cerebrospinal fluid hypocretin levels in 4 patients with PWS without a history of narcolepsy/cataplexy relative to 10 controls and postulated that daytime sleepiness may be due in part to hypothalamic dysfunction; hypocretin is synthesized in the hypothalamus, promotes wakefulness, and suppresses REM sleep. 28, 29 Other authors have reported blunted responses to hypoxia or hypercapnia and paradoxical responses to hypoxia in non-obese PWS patients. 8, 10, 30, 31 In our series, the most common PSG abnormality was oxygen desaturation, followed by elevated AHIs, hypoventilation, snoring, and elevated central apneas. However, PSG abnormalities do not fully explain sleep disturbances. Patients with three or even four PSG abnormalities did not necessarily have abnormally short multiple sleep latencies, an objective measure of daytime sleepiness. Patients who had undergone tonsillectomy and adenoidectomy 25, 31, 35 still had elevated AHI, oxygen desaturations, and/or hypoventilation. A third of the patients also had series of selected patients, as many as 70% had evidence of significant oxygen desaturation, apnea, or hypoventilation.
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Our cohort was a highly selected group (all patients were referred for concern for SDB), and all patients exhibited some form of SDB based on conservative criteria. This could suggest good clinical acumen, but it more likely suggests that the true incidence of SDB is underappreciated. The clinical relevance of some of the milder abnormalities is unclear. Future research could address the relevance, although all patients were referred because of a concern for SDB, and very abnormal studies were not often suspected a priori.
The basis of the sleep abnormalities is controversial. Given the obesity associated with this syndrome, many have postulated obstructive sleep apnea as the basis. Apneas and oxygen desaturations have been found in some series to be the predominant PSG abnormality, and one study suggested a correlation between the BMI, apneas, and oxygen desaturation. 10, 24, 27 Our results also confirmed a correlation between BMI z and AHI. nary problems. The remaining case reports made note of other underlying physiological abnormalities (e.g., increased pulmonary artery pressure, tonsillar and/or adenoidal hypertrophy, sleep apnea) following initiation of GH supplementation; given the small numbers and comorbidities, it would be difficult to ascribe the deaths solely to the hormonal supplementation. 17, 18 Studies of a small series of PWS patients not receiving GH supplementation reported deaths from the neonatal period to adulthood. Although while many of the causes of death were not well characterized, hypoventilation, upper respiratory tract infections, fever and/or gastroenteritis were thought to play a role in the pediatric deaths; other studies have also associated respiratory infections and/or high fever with sudden death in PWS. 23, 33, 34 GH supplementation has several benefits for this patient population: increased final height, less adipose tissue, and increased lean muscle mass. In keeping with these findings, GH-supplemented patients in this cohort had significantly smaller BMI z compared with untreated patients. There were no statistically evidence of central apnea. These data do not allow differentiation between the various proposed pathophysiological bases for the sleep disturbances (i.e., tonsillar hypertrophy and obesity, neurohormonal abnormalities, or blunted central chemoreceptors), but do not exclude any either.
Approximately half of the 37 patients were receiving GH supplementation at the time of the initial PSG. One impetus for this study was publication of several case reports suggesting a link between initiation of GH supplementation and death two to six months later, raising the question of differences in PSG findings between the two groups. [16] [17] [18] This study did not identify differences in PSG parameters between the two groups, and there have been no deaths in the cohort.
Several studies have demonstrated the benefit of GH supplementation, and none of these larger series have reported any deaths in their patient series. [11] [12] [13] [14] 32 Eiholzer and colleagues mentioned in their case report that the patient who died following initiation of GH supplementation had a lifelong history of pulmo- Sleep-Disordered Breathing in Prader-Willi Syndrome alence of SDB in this population), so that the underlying genetic abnormality did not appear to affect this phenomenon. 9, 22 We considered whether the genetic abnormality might correlate with one particular aspect of SDB (i.e., AHI), but our cohort did not yield evidence for a correlation, echoing the findings of from a small case series. 39 The physiologic benefits of GH supplementation have already been demonstrated. This study was undertaken to identify markers (BMI z , genetic abnormality, and/or questionnaires) which might be predictive of underlying SDB. Our cohort did not yield evidence for markers with good predictive ability for SDB. However, a larger BMI z is correlated with a higher AHI. While both GH-treated and -untreated patients exhibited SDB, this does not necessarily imply that GH supplementation does not have a positive effect on SDB. This retrospective study did not follow most of these patients with serial studies to document any individual changes with therapy.
In summary, these findings underscore the importance of having a low threshold for obtaining PSG in PWS, when there is a suspicion of SDB-e.g., snoring, apnea, headaches, or worsening behavior problems. 40 It was particularly worrisome that there were no clues to the severity of the SDB before PSG evaluations-some cases were abnormal enough to warrant immediate hospital admission for urgent pulmonary medicine consultation.
A relatively small number of patients were reviewed, although the rarity of this syndrome makes larger studies uncommon. The primary limitation of this study is its retrospective nature, as well as the multiple comparisons increasing the risk of type I statistical error. However, much of the statistically significant differences were in line with findings from other small series of these patients. Most of the comparisons were not significant, which could represent an underpowered sample. Another limitation of this study was the lack of serial PSGs identifying changes in SDB with therapy. Due to its retrospective nature, very few of the patients had serial studies, and not all were treated with GH therapy. Future larger, prospective, formalized studies could better define the incidence of SDB even in patients not suspected of SDB, the severity of SDB, and as importantly the benefits of clinical intervention.
ABBReviAtioNS
AHI
apnea-hypopnea index BMI z normalized body mass indices EEG electroencephalogram FISH fluorescence in situ hybridization MSLT multiple sleep latency test PLM periodic limb movements significant differences between AHI, central apnea, oxygen nadir, or maximum ETCO 2 between the 2 groups, suggesting that GH does not directly affect these parameters. There was a correlation between the BMI z and AHI, in keeping with results from small case series demonstrating a reduction in obstructive apneas/hypopneas with weight loss. 5, 35 In our cohort, 30 families completed a sleepiness scale based on a modified Epworth Sleepiness Scale; 20 of the scores were ≥10, suggesting an increased propensity for daytime sleepiness. This instrument has been validated in adults who were able to fill out their own questionnaires, but the applicability to children (for whom a proxy completes the questionnaire) has been questioned. 36, 37 The sleepiness scores obtained did not correlate with either the AHI or the MSLT mean latency results. Likewise, the MSLT mean latency, an objective measure of sleepiness, did not correlate with the AHI. The reported findings did not indicate an association between SDB and daytime sleepiness (e.g., 25% of those undergoing MSLT had findings compatible with narcolepsy). Our findings suggest that the pathophysiology of sleep disturbances in PWS is likely to be multifactorial.
We also considered whether the underlying genetic abnormality might affect SDB. Some reports have mentioned certain facial features more commonly associated with certain genetic abnormalities, and there are reports of differences in intelligence and risk for psychosis depending on the genetic subtype. 2, 38 As mentioned earlier, all patients exhibited some form of SDB (a finding in agreement with other studies suggesting a high prev- 
